Thus, a greater understanding of the impact of rebalancing the neurotoxic and neuroprotective branches of the KYN pathway in AD may provide additional mechanistic evidence to support development of a new generation of neuroprotective brain-penetrant KMO inhibitors. This evidence concerns the gene KMO and Alzheimer disease.